This resource page was created to help clinicians gain greater understanding of the many recent advances in the diagnosis and management of rheumatoid arthritis and put them into daily practice.
In addition to articles from The Journal of Musculoskeletal Medicine, you'll find the latest news on rheumatoid arthritis from around the Web. We encourage you to check back regularly, because this information is updated often.
Help us build this page – Send us links to your favorite resources on rheumatoid arthritis. We welcome your comments and suggestions.
ABSTRACT: Evidence of ongoing juvenile idiopathic arthritis (JIA) into adulthood has led to a shift in the treatment paradigm. Most physicians now pursue an approach of early, aggressive combination therapy.
The duration of morning stiffness in patients who have rheumatoid arthritis (RA) correlates better with other patient-reported outcomes than with joint counts and erythrocyte sedimentation rate (ESR).
The dollars being spent on aggregate overall direct medical expenditures for adults with arthritis are almost double the group's share of the population. The societal and individual burden of arthritis has increased, and this increase probably will grow.
Nonadherence to the treatment regimen is a major problem that affects about one-third of patients with rheumatoid arthritis (RA) who use disease-modifying antirheumatic drugs (DMARDs).
MRI for earlier diagnosis of inflammatory arthritis The armamentarium of treatment modalities available to physicians seeing patients with rheumatoid arthritis (RA) and other forms of inflammatory arthritis has increased dramatically in recent years. In particular, the introduction of the biologic disease-modifying antirheumatic drugs (DMARDs), most notably the tumor necrosis factor a (TNF-a) inhibitors, has afforded clinicians new opportunities to mitigate disease progression.
Rheumatoid arthritis (RA) often presents late, when irreversible damage has occurred. More than half of primary care consultations are for joint pain,1 but the average time from initial presentation with symptoms to confirmation of diagnosis of RA is 18 weeks.2
ABSTRACT: No new drug was FDA-approved for gout for close to 45 years, but new drugs are on the market now and others are in development. Established treatments often are effective, but each has limitations. In 2009, the FDA approved a nongeneric colchicine for acute gout. More »
Neither preterm birth nor being breastfed is significantly associated with the incidence of rheumatoid arthritis (RA). These findings are consistent with those of previous investigations for a null association between RA and gestational age, but the previously reported protective effect of being... More »
Plantar pressures measurement, frequently used in rehabilitation and related research, is highly reliable in evaluating patients with rheumatoid arthritis (RA), according to researchers at the University Rehabilitation Institute, Republic of Slovenia, in Ljubljana. On the basis of their findings,... More »
The chronic inflammation of rheumatoid arthritis (RA) leads to impairment of bone biomechanics in terms of stiffness, ductility, and ultimate strength (fracture), according to researchers at the Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de... More »
Although NSAIDs are the most effective treatment for persons who experience the pain of osteoarthritis (OA), the risk of adverse effects with NSAIDs may outweigh the benefits in many older patients. The GI risk is well known; increased attention has been paid recently to the cardiovascular risk. The... More »
